Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil.

Müller TE, Ellwanger JH, Michita RT, Matte MCC, Renner JDP.

An Acad Bras Cienc. 2017 May;89(1 Suppl 0):497-504. doi: 10.1590/0001-3765201720160355. Epub 2017 May 4.

2.

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.

Soeria-Atmadja S, Österberg E, Gustafsson LL, Dahl ML, Eriksen J, Rubin J, Navér L.

PLoS One. 2017 Sep 8;12(9):e0181316. doi: 10.1371/journal.pone.0181316. eCollection 2017.

3.

Cytochrome 2B6 polymorphism and efavirenz-induced central nervous system symptoms : a substudy of the ANRS ALIZE trial.

Gallien S, Journot V, Loriot MA, Sauvageon H, Morlat P, Reynes J, Reliquet V, Chêne G, Molina JM; ANRS 099 ALIZE trial study group.

HIV Med. 2017 Sep;18(8):537-545. doi: 10.1111/hiv.12488. Epub 2017 Feb 1.

4.

Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.

Mukonzo JK, Owen JS, Ogwal-Okeng J, Kuteesa RB, Nanzigu S, Sewankambo N, Thabane L, Gustafsson LL, Ross C, Aklillu E.

PLoS One. 2014 Jan 31;9(1):e86919. doi: 10.1371/journal.pone.0086919. eCollection 2014.

5.

The CYP2B6 G516T polymorphism influences CD4+ T-cell counts in HIV-positive patients receiving antiretroviral therapy in an ethnically diverse region of the Amazon.

Queiroz MAF, Laurentino RV, da Silva Graça Amoras E, Araújo MSM, Gomes STM, Lima SS, Vallinoto ACR, de Oliveira Guimarães Ishak M, Ishak R, Machado LFA.

Int J Infect Dis. 2017 Feb;55:4-10. doi: 10.1016/j.ijid.2016.12.002. Epub 2016 Dec 9.

6.

Brief Report: CYP2B6 516G>T Minor Allele Protective of Late Virologic Failure in Efavirenz-Treated HIV-Infected Patients in Botswana.

Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay M, Moorthy GS, Ratshaa BR, Han X, Steenhoff AP, Mosepele M, Strom BL, Aplenc R, Bisson GP, Gross R.

J Acquir Immune Defic Syndr. 2017 Aug 1;75(4):488-491. doi: 10.1097/QAI.0000000000001442.

7.

CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.

Chang JL, Lee SA, Tsai AC, Musinguzi N, Muzoora C, Bwana B, Boum Y 2nd, Haberer JE, Hunt PW, Martin J, Bangsberg DR, Kroetz DL, Siedner MJ.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):982-992. doi: 10.1089/AID.2018.0062. Epub 2018 Aug 15.

8.

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.

Meng X, Yin K, Wang J, Dong P, Liu L, Shen Y, Shen L, Ma Q, Lu H, Cai W.

PLoS One. 2015 Jun 24;10(6):e0130583. doi: 10.1371/journal.pone.0130583. eCollection 2015.

9.

CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.

Powers V, Ward J, Gompels M.

HIV Med. 2009 Sep;10(8):520-3. doi: 10.1111/j.1468-1293.2009.00718.x. Epub 2009 May 21.

10.

Efavirenz and the CNS: what we already know and questions that need to be answered.

Apostolova N, Funes HA, Blas-Garcia A, Galindo MJ, Alvarez A, Esplugues JV.

J Antimicrob Chemother. 2015 Oct;70(10):2693-708. doi: 10.1093/jac/dkv183. Epub 2015 Jul 22. Review.

PMID:
26203180
11.

Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.

Aurpibul L, Chotirosniramit N, Sugandhavesa P, Kosashunhanan N, Thetket S, Supindham T, Piyamongkol W, Supparatpinyo K.

Curr HIV Res. 2012 Dec;10(8):653-60.

PMID:
22950382
12.

CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.

Dhoro M, Zvada S, Ngara B, Nhachi C, Kadzirange G, Chonzi P, Masimirembwa C.

BMC Pharmacol Toxicol. 2015 Mar 27;16:4. doi: 10.1186/s40360-015-0004-2.

13.

CYP2B6 genotypes and early efavirenz-based HIV treatment outcomes in Botswana.

Gross R, Bellamy SL, Ratshaa B, Han X, Vujkovic M, Aplenc R, Steenhoff AP, Mosepele M, Moorthy G, Zuppa AF, Strom BL, Bisson GP.

AIDS. 2017 Sep 24;31(15):2107-2113. doi: 10.1097/QAD.0000000000001593.

14.

Efavirenz in the therapy of HIV infection.

Rakhmanina NY, van den Anker JN.

Expert Opin Drug Metab Toxicol. 2010 Jan;6(1):95-103. doi: 10.1517/17425250903483207. Review.

15.

Sleep quality in efavirenz-treated Chinese HIV patients - comparing between GT and GG genotype of CYP2B6-516 G/T polymorphisms.

Lee SS, To KW, Lee MP, Wong NS, Chan DP, Li PC, Cheung SW, Chan RC.

Int J STD AIDS. 2014 Mar;25(3):193-200. doi: 10.1177/0956462413498581. Epub 2013 Jul 23.

PMID:
23970651
16.

In Vivo Profiling and Distribution of Known and Novel Phase I and Phase II Metabolites of Efavirenz in Plasma, Urine, and Cerebrospinal Fluid.

Aouri M, Barcelo C, Ternon B, Cavassini M, Anagnostopoulos A, Yerly S, Hugues H, Vernazza P, Günthard HF, Buclin T, Telenti A, Rotger M, Decosterd LA; Swiss HIV Cohort Study.

Drug Metab Dispos. 2016 Jan;44(1):151-61. doi: 10.1124/dmd.115.065839. Epub 2015 Nov 9.

PMID:
26553012
17.

Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.

Puthanakit T, Tanpaiboon P, Aurpibul L, Cressey TR, Sirisanthana V.

Antivir Ther. 2009;14(3):315-20.

PMID:
19474465
18.

Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana.

Vujkovic M, Bellamy SL, Zuppa AF, Gastonguay MR, Moorthy GS, Ratshaa B, Han X, Steenhoff AP, Mosepele M, Strom BL, Bisson GP, Aplenc R, Gross R.

Pharmacogenomics J. 2018 Sep;18(5):678-688. doi: 10.1038/s41397-018-0028-2. Epub 2018 Jun 1.

19.
20.

Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation.

Pinillos F, Dandara C, Swart M, Strehlau R, Kuhn L, Patel F, Coovadia A, Abrams E.

BMC Infect Dis. 2016 Feb 2;16:56. doi: 10.1186/s12879-016-1381-x.

Supplemental Content

Support Center